Pre-clinical Safety Review of COMP360 (Psilocybin) in the Treatment of Depression

This academic report focuses on a pre-clinical safety review of COMP360, a synthetic psilocybin-based drug being developed for treating depression and other psychiatric conditions. The document outlines the drug's overview, including its pharmacodynamics (how it affects the body) and pharmacokinetics (how the body processes it), and details its known safety information and side effects. Furthermore, it explains the International Council for Harmonisation (ICH) safety guidelines, specifically ICH S7 for pharmacology studies and ICH S2 (R1) for genotoxicity studies, concluding with recommended non-clinical safety studies for COMP360 based on its physiological impact. The report highlights COMP360's promise as a breakthrough therapy while emphasizing the need for rigorous safety assessments in controlled clinical environments.